Pramlintide
Also known as: Symlin, AC137, Amylin analog
Pramlintide (also called Symlin or AC137) is an FDA-approved amylin analog. Pramlintide is a synthetic analog of human amylin in which three proline substitutions prevent the self-aggregation that makes native human amylin unsuitable as a drug. It binds amylin receptors — calcitonin receptor cores paired with receptor activity-modifying proteins — in the area postrema.
For research use only.
Key Facts
- CAS
- 151126-32-8
- Molecular Weight (MW)
- 3949.4 g/mol
- Half-life
- ~48 minutes
- FDA status
- Approved
- Administration Route
- Subcutaneous
- Frequency
- Before major meals
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- Amylin receptor
Research summary
FDA-approved amylin analog (Symlin) used with mealtime insulin in type 1 and type 2 diabetes. Hypoglycemia risk requires insulin dose reduction.
Peptide Library's Pramlintide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- T1D typically 15–60 mcg before meals; T2D 60–120 mcg (label)
- Frequency
- Before major meals
- Cycle
- Chronic with insulin as prescribed
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
- Injection Sites
- AbdomenThigh
- Timing Notes
- Educational catalog only — not medical advice
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Pramlintide is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C171H267N51O53S2 |
|---|---|
| Molecular weight | 3949.4 g/mol |
| CAS number | 151126-32-8 |
| Half-life | ~48 minutes |
| Appearance | Solution in pen/vial |
| Formulation | Solution |
| PubChem CID | 70691388 |
| FDA UNII | D3FM8FA78T |
| ChEMBL | CHEMBL2103758 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Pramlintide is a synthetic analog of human amylin in which three proline substitutions prevent the self-aggregation that makes native human amylin unsuitable as a drug. It binds amylin receptors — calcitonin receptor cores paired with receptor activity-modifying proteins — in the area postrema. Three effects follow: gastric emptying slows, inappropriate post-prandial glucagon secretion is suppressed, and satiety signalling increases. Together these blunt the post-meal glucose rise through a route entirely separate from insulin. Because it does not itself lower glucose but amplifies insulin action, it is approved only as an adjunct to mealtime insulin, and insulin dose reduction is required when it is started.
Origin
Proline-substituted human amylin analog.
Targets
Studies
- Amylin analogs for the treatment of obesity without diabetes: present and future
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
- Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis
- Pramlintide
- Pramlintide
Regulatory & research status
Pramlintide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Availability | Prescription-Only |
| WADA (sport) | Permitted |
| Library classification | FDA-Approved |
Benefits
Potential Side Effects
Side Effects
- Nausea
- Severe hypoglycemia with insulin
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Pramlintide: frequently asked questions
What is Pramlintide?
FDA-approved amylin analog (Symlin) used with mealtime insulin in type 1 and type 2 diabetes. Hypoglycemia risk requires insulin dose reduction.
How does Pramlintide work?
Pramlintide is a synthetic analog of human amylin in which three proline substitutions prevent the self-aggregation that makes native human amylin unsuitable as a drug. It binds amylin receptors — calcitonin receptor cores paired with receptor activity-modifying proteins — in the area postrema.
Is Pramlintide FDA approved?
Yes. Pramlintide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What is the half-life of Pramlintide?
Reported half-life for Pramlintide is ~48 minutes. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Pramlintide banned in sport?
Pramlintide is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.
What peptides are similar to Pramlintide?
Compounds most often compared with Pramlintide include Cagrilintide, Petrelintide, CagriSema and Amycretin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Symlin labelExternal reference
- Amylin analogs for the treatment of obesity without diabetes: present and future — Expert Rev Clin Pharmacol, 2024External reference
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept — Mol Metab, 2025External reference
- Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis — J Clin Endocrinol Metab, 2015External reference
- Pramlintide, 2012External reference
- Pramlintide, 2006External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Pramlintide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Pramlintide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →